Press Releases

 
Press Releases
Date Title and Summary View
Oct 24, 2013 SALT LAKE CITY, Oct. 24, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it will present data this week at the American Society of Human Genetics (ASHG) annual meeting in Boston showing that the Myriad myRisk Hereditary Cancer test meets rigorous quality standards and provides clinical sequencing results equivalent to 9...
Oct 23, 2013 SALT LAKE CITY, Oct. 23, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the first fiscal quarter 2014 following the close of market on Tuesday, Nov. 5, 2013. The Company also will host a conference call on Tuesday, Nov. 5, 2013 at 4:30 p.m. ET to discuss the financial re...
Oct 14, 2013 SALT LAKE CITY, Oct. 14, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that results from a verification study showed the Myriad myPath™ Melanoma test effectively differentiated malignant melanoma from benign skin lesions. The clinically-actionable information provided by myPath Melanoma will empower healthcare p...
Oct 9, 2013 SALT LAKE CITY, Oct. 9, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it will present data showing the high prevalence and overlap between hereditary colon cancer and hereditary breast and ovarian cancer in patients previously diagnosed with endometrial and ovarian cancer. Myriad is presenting this data and another he...
Oct 7, 2013 SALT LAKE CITY, Oct. 7, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced new clinical data from a study with myRisk Hereditary Cancer, a 25-gene hereditary cancer panel, that showed a 60 percent increase in mutations detected in cancer predisposition genes in patients with a prior history of colon cancer and/or polyps. M...
Oct 1, 2013 SALT LAKE CITY, Oct. 1, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that BioMarin Pharmaceutical Inc. will use Myriad's BRACAnalysis® test in connection with its pivotal Phase 3 clinical studies for BMN 673. BMN 673 is a novel, orally-active PARP inhibitor designed to induce synthetic lethality in BRCA-deficien...
Sep 25, 2013 SALT LAKE CITY, Sept. 25, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced new data published in Clinical Cancer Research that showed the myPlan Lung Cancer test is a significant predictor of lung cancer death in patients with early-stage, resectable lung adenocarcinoma and may be a valuable tool for selecting which earl...
Sep 5, 2013 SALT LAKE CITY, Sept. 5, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Mark Capone, President of Myriad Genetic Laboratories, Inc. is scheduled to present at the Morgan Stanley Global Healthcare Conference, at 2:55 p.m. Eastern on September 10, 2013 in New York City. The presentation will be available to ...
Sep 5, 2013 SALT LAKE CITY, Sept. 5, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it has launched myRisk Hereditary Cancer, a new multi-gene diagnostic test that will provide increased sensitivity by analyzing 25 genes associated with eight major cancers including: breast, colorectal, ovarian, endometrial, pancreatic, prost...
Sep 4, 2013 SALT LAKE CITY, Sept. 4, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it has entered into an expanded, nonexclusive global collaboration agreement with AstraZeneca to provide companion diagnostics for the olaparib Phase 3 clinical development program. Olaparib is an investigational orally active poly-ADP ribose ...
Page: FirstPrevious ...
7
... NextLast
= add release to Briefcase